Elixir Medical bioresorbable stent gets CE mark; Alnylam announces Phase I success for hemophilia med;

> Elixir Medical has received a CE mark for its DESolve 100 novolimus-eluting bioresorbable coronary scaffold, named after its 100-micron strut profile and designed to degrade within a year. It will be available commercially in 2015. Story

> Alnylam ($ALNY) said ALN-AT3, an RNAi treatment for hemophilia and other bleeding disorders, succeeded in a Phase I trial. Release

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.